Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Share this content:
Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid l
Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid l

Switching to 2-year consolidation therapy with nilotinib may lead to improved rates of deep molecular responses (DMR; MR4.5, BCR-ABL1IS ≤ 0.0032%) among patients with chronic-phase chronic myeloid leukemia (CMP-CP) who achieved major molecular response (MMR) with long-term imatinib therapy, according to a study published in the International Journal of Hematology.1

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of DMR and perhaps even treatment-free remission among patients with newly diagnosed CML-CP.

In the STAT1 phase 2 study in Japan, researchers enrolled 76 patients with CML-CP who had achieved MMR but still had persistent BCR-ABL1 positivity with imatinib, and switched them to nilotinib 300 mg twice daily for 2 years. Patients were treated with imatinib for a median of 69.0 months, and the median time to MMR on imatinib therapy was 20.4 months. The median age of participants was 55 years old.

Results showed that the cumulative rate of MR4.5 increased over time. Overall, 63.5% of patients achieved MR4.5; the rate of DMR at 12 and 24 months was 27.0% (90% CI, 18.7%-36.8%) and 44.6% (90% CI, 34.7%-54.8%), respectively. Researchers estimated that the median duration of therapy to reach MR4.5 was 18.2 months.

The only independent predictive biomarker across multiple logistic regression analysis for achieving 24-month MR4.5 was the frequency of ABCG2 431C/A + A/A genotype.

All-grade adverse events (AEs) were reported in 56.6% of patients, and 17.5% of patients experienced grade 3 to 4 AEs. The most commonly observed treatment-related AEs included elevated total bilirubin, elevated ALT/AST, fatigue, and rash.

The authors concluded that findings “suggested that switching to [nilotinib] safely led to a DMR in patients with MMR, but without MR4.5 on [imatinib] therapy. Switching to nilotinib from imatinib and a 2-year consolidation therapy with this agent may be an efficacious strategy to achieve DMR and it may enable a greater proportion of CML-CP patients to be eligible for future discontinuation studies.”

Reference

  1. Noguchi S, Nakaseko C, Nishiwaki K, et al. Switching to nilotinib is associated with deeper molecular response in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan [published online April 30, 2018]. Inter J Hematol. doi: 10.1007/s12185-018-2459-6

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs